Health Service Circular

Series number:

HSC 1999/176

Issue date:

6th August 1999

Review date:

31st March 2000

Category:

Clinical Effectiveness

Status:

Information

 

for information only

 

To:

Regional Directors
Regional Directors of Public Health
Regional Directors of Research Development
Regional Advisors in General Practice
Health Authorities (England) - Chairmen
Health Authorities (England) - Chief Executives
Health Authorities (England) - Chief Nurses
Health Authorities (England) - Director of Public Health
NHS Trusts (England) - Chairmen
NHS Trusts (England) - Chief Executives
NHS Trusts (England) - Medical Directors
Primary Care Groups (England) - Chairmen

Cc

CHC Chairmen

Further details from:

Charles Dobson
Room 6E57
NHS Executive
Quarry House
Quarry Hill
Leeds LS2 7UE
Tel: 0113 254 5227

Additional copies of this document can be obtained from:

Department of Health
PO Box 777
London SE1 6XH
or
Fax 01623 724524

It is also available on the Department of Health website at
http://tap.ccta.gov.uk

 

© Crown copyright 1999

 
National Institute for Clinical Excellence: initial work programme
Summary
This HSC
i sets out the proposed initial work programme for the National Institute for Clinical Excellence (NICE)
ii explains the basis on which NICE will carry out appraisals of existing and new health interventions
iii asks NHS bodies to continue with local arrangements for the managed introduction of new technologies for any interventions which are not referred to NICE, or where NICE's guidance is not available at the time the technology first becomes available.
   
Action
  NHS bodies are asked to bring the contents of this circular to the attention of all clinical staff.
   
The overall context
1 The consultation papers A first class service: quality in the new NHS (in England) and Quality care and clinical excellence (in Wales) set out the government's plans for a new National Institute for Clinical Excellence (NICE) which would give guidance to the NHS in three board areas:
   
 
i appraisals of individual, new and existing, health interventions
ii Clinical guidelines giving best practice advice for whole conditions or patient groups;
iii clinical audit methodologies.
   
2. Earlier this year, the government issued a follow-up discussion paper "Faster access to modern treatment" with proposals on how NICE should carry the first of these functions. In the light of the response to this discussion paper, ministers in consultation with the National Assembly for Wales have now agreed a "Memorandum of Understanding" setting out the basis on which NICE will operate; a copy is available on the Department of Health's website (www.doh.gov.uk)
   
3. The Department of Health, in consultation with the National Assembly for Wales, has identified possible topics for referral to NICE from two main sources:
   
 
i information on new health interventions is gathered and prioritised by the Horizon Scanning Centre at the University of Birmingham;
ii possible topics for guidance on existing health interventions or areas of clinical practice have been identified in the course of work on National Service Frameworks, supplemented by additional proposals from regional offices.
   
4. In either case, possible topics are examined to determine whether the more appropriate form of guidance would be an appraisal (of an individual intervention), a clinical guidance or a clinical audit methodology. Proposals are then considered in relation to the Government's health priorities, to their intrinsic significance to NHS patient services, and to the potential for NICE to "add value".
   
5.

If a new intervention is not referred to NICE, this does not imply any judgement on whether the intervention(s) in question are clinically or cost effective. NHS bodies should continue to use exiting arrangements to access the publicly available evidence and to determine local policies for the managed entry of the new intervention. The same principle should apply if an intervention has been referred to NICE but guidance is not yet available at the point which the new intervention is first introduced. In the case of new pharmaceuticals, the New Drugs in Development bulletin published by the National Prescribing Centre and Drug Information Pharmacists Group may be a helpful source of information.

 

Initial work programme for NICE

6. Annex A sets out the initial list of topics which ministers propose to refer to NICE. Interested parties have been notified where appropriate and invited to submit comments. Ministers' final decisions will be announced in due course. Further topics, in particular for clinical guidelines and audit methodologies, will be announced later this year.
   

Future work programme

7. The NHS Coordinating Centre for Health Technology Assessment (NCCHTA) will shortly be piloting a revised process to enable NHS bodies to submit proposals for topics which might be suitable either for research under the NHS R&D programme or for guidance from NICE. This will replace the previous annual bidding round which was limited to research proposals.
   

Contact points:

For the selection of topics:
Charles Dobson (appraisals)
Nick Clarke (guidelines)
For NICE: Andrew Dillon
   
http://www.doh.gov.uk
http://www.nice.org.uk
   
Associated Documentation
PROPOSED LIST OF TOPICS FOR REFERRAL TO NICE
   
A. APPRAISALS OF INDIVIDUAL HEALTHCARE INTERVENTIONS
Technology Indication
 
(NICE to begin consideration in autumn 1999)
   
Hip prostheses Hip replacement
Advances in hearing aids Hearing disability

Routine extraction of (non-symptomatic) wisdom teeth

Dental care
Liquid based cytology Cervical Screening
Coronary artery stent developments disease Treatment of coronary heart
Taxanes (paclitaxel and docetaxel)* Breast cancer and ovarian cancer
Inhaler systems Childhood asthma
Proton pump inhibitors Dyspepsia
Inteferon beta* Secondary progressive MS and early MS (also for existing indication of relapsing/remitting MS)
glatiramer* Relapsing-remitting MS
Zanamavir and oseltamivir* Influenza
   
ii (NICE to consider in early 2000)
   
Laparoscopic surgery Various applications, including treatment of hernia and colorectal cancer
Wound care (selected) Various applications
Implantable cardioverter defribillators Heart arrythmias
Autologous cartilage transplantation Treatment of cartilage injury
Riluzole Motor neurone disease
methylphenidate (Ritalin, Equasym) Hyperactivity in childhood
Ribavirin/alpha interferon Hepatitis C
Cox-ll inhibitors* Rheumatic disorders
Orlistat/sibutramine* Obesity
Glitazones* Diabetes
Glycoprotein llb/llla receptor Inhibitors Unstable angina and acute coronary syndrome
New pharmaceutical treatments* Alzheimer's disease
   
*some of these pharmaceuticals are not currently licensed for the indication(s) for which it is proposed they should be referred to NICE, although we understand that a license application will be submitted or is being considered by the appropriate authorities. Inclusion in this list does not imply any assumption that a license will be granted. NICE will not finalise and issue its guidance until the license application has been determined.
 

This circular has been issued by:

 
Dame Yvonne Moores
Chief Nursing Officer / Director of Nursing